Project Grant RF1AG094739
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $195,041 supports research to elucidate the role of cardiovascular disease in the development of Alzheimer's disease in individuals with Down syndrome. The 2-year project will leverage data from the Alzheimer's Biomarker Consortium for Down Syndrome to develop innovative statistical models combining Bayesian inference and machine learning. These methods will explore...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $322,000.00 to Case Western Reserve University to perform the following: Analyze electroencephalographic (EEG) and plasma Alzheimer's disease (AD) biomarker data collected during a previous clinical trial studying the effects of the drug memantine on adolescents and young adults with Down syndrome. The analysis will examine the...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
- This Project Grant award, funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), is focused on investigating the susceptibility of basal forebrain cholinergic neurons in individuals with Down syndrome. The key objectives of this $111,783 award, which runs from November 9, 2024 to June 30, 2026, are to: 1) determine if there are fewer basal forebrain cholinergic neurons and earlier accumulation of Alzheimer's disease pathology in the early...
- The National Institutes of Health Trans-NIH Research Support program awarded a $4,010,262 Project Grant to the University of Illinois to study the role of amyloid precursor protein in neurogenesis and Alzheimer's disease pathology in Down syndrome. The three-year grant will support research examining how overexpression of amyloid precursor protein, which is located on chromosome 21 and thus triplicated in Down syndrome, impacts neural stem cell proliferation, neuronal differentiation, and...
- This Project Grant award from the Department of Health and Human Services National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) provides $446,096 to the University of Illinois to develop and implement community-based participatory health research with young adults with Down syndrome. The project aims to reflect the perspectives and lived experiences of adults with Down syndrome, including those from underserved and underrepresented communities, to reduce health disparities and...
- The federal Cooperative Agreement award U01HD116463, titled "The Infant Down Syndrome Brain and Behavior Study", is funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $2,927,457 award will support a longitudinal study to collect multimodal neuroimaging, cognitive/behavioral data, and social communication measures in a cohort of 100 infants with Down syndrome and 50 typically developing controls. The study aims to...
- This $2,598,199 Cooperative Agreement, awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), will support a multi-center, multi-disciplinary research project titled "Advancing the Lives & Health of Youth and Young Adults with Down Syndrome (ALLY-DS)." The project aims to establish a diverse cohort of individuals with Down syndrome for comprehensive longitudinal phenotyping, including multi-omics data...
- The Department of Health and Human Services National Institutes of Health (NIH) awarded a $1,488,578 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of Wisconsin-Madison to develop humanized mouse models for studying Down syndrome (DS) immune responses. The project aims to: 1) Create DS hypoimmune gene-edited induced pluripotent stem cell lines and differentiate them into cardiovascular cell therapies, assessing in vitro DS immune responses; and 2)...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,257,163 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) as a potential treatment for Alzheimer's disease in individuals with Down syndrome. The 5-year project, beginning on Jul 1, 2025, will first measure FSH levels across the lifespan in mouse models of Down syndrome...
This Project Grant award of $1,346,873 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is supporting research to establish an Alzheimer's disease biomarker clock in individuals with Down syndrome. The project aims to utilize positron emission tomography (PET) imaging and plasma analytes to longitudinally assess changes in amyloid, tau, and neurodegeneration biomarkers prior to the onset of dementia in this population. This research will address key challenges in recruiting individuals with Down syndrome into Alzheimer's disease clinical trials, such as understanding biomarker progression differences compared to neurotypical adults. The University of Wisconsin-Madison is the awardee for this project, which is scheduled to run from September 15, 2025 through August 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 9/12/25 |